Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06061718
PHASE3

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Sponsor: Glaukos Corporation

View on ClinicalTrials.gov

Summary

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

Official title: Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery

Key Details

Gender

All

Age Range

45 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-09-11

Completion Date

2024-12-20

Last Updated

2024-06-03

Healthy Volunteers

No

Interventions

DRUG

iDose TR

anchored intracameral implant containing travoprost

Locations (1)

Glaukos Clinical Study Site

Yerevan, Armenia